Results 161 to 170 of about 2,436,024 (405)

Non-Interventional Observational Analysis of the Clinical Outcomes with IO-FIVE (Immune-Oncology Fast In Vivo Efficacy Test) in Lymphoma Patients [PDF]

, 2023
Chanjuan Jin, Bin Xie, Di Zhou, Yanan Zhao, Hua Wei, Zhenle Bi, Yang Liu, Kaimeng Hu, Lintao Bi, Danyi Wen   +9 more
openalex   +1 more source

OncoKB: A Precision Oncology Knowledge Base.

JCO Precision Oncology, 2017
D. Chakravarty, Jianjiong Gao, Sarah M. Phillips, Ritika Kundra, Hongxin Zhang, Jiaojiao Wang, J. Rudolph, R. Yaeger, Tara E. Soumerai, Moriah H. Nissan, Matthew T. Chang, S. Chandarlapaty, T. Traina, P. Paik, A. Ho, F. Hantash, A. Grupe, S. Baxi, M. Callahan, A. Snyder, Ping Chi, D. Danila, M. Gounder, J. Harding, M. Hellmann, G. Iyer, Y. Janjigian, T. Kaley, D. Levine, M. Lowery, A. Omuro, M. Postow, D. Rathkopf, A. Shoushtari, N. Shukla, M. Voss, Ederlinda Paraiso, A. Zehir, M. Berger, B. Taylor, L. Saltz, Gregory Riely, M. Ladanyi, D. Hyman, J. Baselga, P. Sabbatini, D. Solit, N. Schultz   +47 more
semanticscholar   +1 more source

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

Molecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge   +18 more
wiley   +1 more source

Embolotherapy for Hepatic Oncology: Current Perspectives and Future Directions

, 2020
Raazi Bajwa, David C. Madoff, Sirish Kishore   +2 more
openalex   +2 more sources

HTA94 Challenges Facing the Health Technology Assessment (HTA) Submissions of Second Line Treatments for Advanced Oncology [PDF]

, 2023
Sneha Bhadti, Gabrielle Redhead, Sophie Tatman, Shona Lang   +3 more
openalex   +1 more source

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source

Age-Dependent Prognostic Effect by Mitosis-Karyorrhexis Index in Neuroblastoma: A Report from the Children's Oncology Group

, 2014
Risa Teshiba, Shinya Kawano, Larry Wang, Lejian He, Arlene Naranjo, Wendy B. London, Robert C. Seeger, Julie M. Gastier‐Foster, A. Thomas Look, Michael D. Hogarty, Susan L. Cohn, John M. Maris, Julie R. Park, Hiroyuki Shimada   +13 more
openalex   +1 more source

Role of non‐chromosomal birth defects on the risk of developing childhood Hodgkin lymphoma: A Children's Oncology Group study [PDF]

, 2023
Erin C. Peckham‐Gregory, Lucas Maschietto Boff, Jeremy M. Schraw, Logan G. Spector, Amy M. Linabery, Erik B. Erhardt, Karina Braga Ribeiro, Carl E. Allen, Michael E. Scheurer, Philip J. Lupo   +9 more
openalex   +1 more source

Tumour-associated macrophages as treatment targets in oncology

Nature Reviews Clinical Oncology, 2017
A. Mantovani, F. Marchesi, A. Malesci, L. Laghi, P. Allavena   +4 more
semanticscholar   +1 more source

Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism

Molecular Oncology, EarlyView.
Adaptaquin selectively kills glioma stem cells while sparing differentiated brain cells. Transcriptomic and proteomic analyses show Adaptaquin disrupts iron and cholesterol homeostasis, with iron chelation amplifying cytotoxicity via cholesterol depletion, mitochondrial dysfunction, and elevated reactive oxygen species.
Adrien M. Vaquié, Davod R. Shah, Eliane E. S. Brechbühl, Michael McNicholas, Zhaoyang Xu, John H. Stockley, Laura Morcom, Diana Gold Diaz, Gemma C. Girdler, Rachel V. Seear, Gabriel Balmus, Rajiv R. Ratan, Harry Bulstrode, James A. Nathan, Manav Pathania, Kevin M. Brindle, David H. Rowitch   +16 more
wiley   +1 more source